JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Arcus Biosciences Inc

Fermé

SecteurSoins de santé

16.76 0.96

Résumé

Variation du prix de l'action

24h

Actuel

Min

16.4

Max

16.95

Chiffres clés

By Trading Economics

Ventes

132M

160M

Employés

627

EBITDA

126M

4M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+79.11% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

882M

1.9B

Ouverture précédente

15.8

Clôture précédente

16.76

Sentiment de l'Actualité

By Acuity

37%

63%

127 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Neutral Evidence

Arcus Biosciences Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 oct. 2025, 22:47 UTC

Acquisitions, Fusions, Rachats

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 oct. 2025, 22:13 UTC

Acquisitions, Fusions, Rachats

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 oct. 2025, 21:20 UTC

Résultats

Correction to IBM 3Q Sales Jump Article

22 oct. 2025, 20:57 UTC

Résultats

SAP Posts Higher 3Q Revenue, Operating Profit

22 oct. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 oct. 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 oct. 2025, 23:41 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 oct. 2025, 23:38 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 oct. 2025, 23:15 UTC

Résultats

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 oct. 2025, 22:28 UTC

Market Talk

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 oct. 2025, 22:02 UTC

Résultats

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 oct. 2025, 21:59 UTC

Acquisitions, Fusions, Rachats

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 oct. 2025, 21:58 UTC

Acquisitions, Fusions, Rachats

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 oct. 2025, 21:57 UTC

Acquisitions, Fusions, Rachats

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 oct. 2025, 21:56 UTC

Acquisitions, Fusions, Rachats

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 oct. 2025, 21:47 UTC

Acquisitions, Fusions, Rachats

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 oct. 2025, 21:47 UTC

Résultats

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 oct. 2025, 21:47 UTC

Acquisitions, Fusions, Rachats

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 oct. 2025, 21:46 UTC

Acquisitions, Fusions, Rachats

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 oct. 2025, 21:45 UTC

Acquisitions, Fusions, Rachats

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 oct. 2025, 21:45 UTC

Acquisitions, Fusions, Rachats

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 oct. 2025, 21:28 UTC

Market Talk
Résultats

Correction to Alcoa Tariff Market Talk

22 oct. 2025, 21:25 UTC

Résultats

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 oct. 2025, 21:17 UTC

Résultats

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 oct. 2025, 21:09 UTC

Market Talk
Résultats

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 oct. 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

22 oct. 2025, 20:59 UTC

Résultats

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 oct. 2025, 20:51 UTC

Résultats

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 oct. 2025, 20:44 UTC

Résultats

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Comparaison

Variation de prix

Arcus Biosciences Inc prévision

Objectif de Prix

By TipRanks

79.11% hausse

Prévisions sur 12 Mois

Moyen 32.33 USD  79.11%

Haut 54 USD

Bas 14 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

11

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

8.01 / 8.75Support & Résistance

Court Terme

Neutral Evidence

Moyen Terme

Neutral Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

127 / 371Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
help-icon Live chat